A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) in Healthy Women.

This study has been completed.
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00709332
First received: June 30, 2008
Last updated: June 6, 2011
Last verified: April 2010
  Purpose

The purpose of the study is to assess the effect of folic acid administration on the blood level and the breakdown products of oral contraceptive (OC) [250 mcg NGM/35 mcg EE] tablets.


Condition Intervention Phase
Drug Interactions
Contraception
Pharmacokinetics
Drug: Norgestimate; Ethinyl Estradiol; Folic acid
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: An Open-label Pharmacokinetic Drug Interaction Study of Folic Acid and 250 Mcg NGM/35 Mcg E E (ORTHO-CYCLEN) in Healthy Women.

Resource links provided by NLM:


Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Primary Outcome Measures:
  • Evaluate the pharmacokinetic drug interaction between folic acid and OC (250 mcg NGM and 35 mcg EE) as measured by the pharmacokinetics of the active breakdown products of NGM, (norelgestromin [NGMN], and norgestrel [NG]) and EE.

Secondary Outcome Measures:
  • Safety is also assessed.

Enrollment: 47
Study Start Date: January 2005
Study Completion Date: February 2005
Detailed Description:

This is an open-label, randomized (study drug assigned by chance), single-center, pharmacokinetic interaction study. Healthy adult women who met the prestudy eligibility criteria were randomized to 1 of 2 treatment groups. The randomization was balanced using permuted blocks. Healthy volunteers in Group 1 were to receive a single oral dose of 250 µg NGM/35 mcg EE (1 tablet) on Days 1 and 17, and 1 mg of folic acid on Days 4 through 18. Healthy volunteers in Group 2 were to receive a single, oral 1 mg dose of folic acid on Days 1 and 17, and 1 tablet on Days 2 through 17. Serial blood samples were to be collected from each healthy volunteer on Days 1 and 17 before dosing and at specified times for up to 72 hours after dosing for pharmacokinetic evaluation. Healthy volunteers were to be confined overnight at the study unit on Days -1 and 16 for an overnight fast of at least 8 hours before dosing on Days 1 and 17. Healthy volunteers were to remain confined at the study unit until the 24-hour blood samples were collected on Days 2 and 18. Safety was based on the incidence of adverse events, and on changes in clinical laboratory values, vital signs, electrocardiograms, and physical and gynecological examination findings. The Sponsor prematurely terminated this study on 14 February 2005 because of errors made at the study site in healthy volunteer randomization, the timing of blood draws, and handling of laboratory samples. As a result of these errors, the pharmacokinetic samples collected were not analyzed, and a new study was initiated (NRGMON-CON-1006). Due to the premature termination of the study, no healthy volunteer received more than 9 days of therapy. Most healthy volunteers completed the screening and premature termination procedures.

Oral contraceptives tablet (250 mcg NGM/35 mcg EE); Folic acid tablet (1 mg). Group 1: Single OC tablet on Days 1 and 17, 1 folic acid tablet on Days 4 to 18. Group 2: Single folic acid tablet on Days 1 and 17, 1 OC tablet on Days 2 to 17. The study drugs were to be taken with 240 mL (8 oz) of water at approximately 8:00 a.m. Healthy volunteers were required to fast for a minimum of 8 hours before dosing on Days 1 and 17.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy
  • Nonpregnant
  • Nonlactating
  • Nonsmoking women
  • Weighing at least 110 pounds
  • With regular menstrual cycles
  • A body mass index between 16 and 29.9 kg/m2
  • And a hematocrit of at least 36%

Exclusion Criteria:

  • History or presence of disorders commonly accepted as contraindications to sex hormonal therapy including: thromboembolic disorders cerebral vascular or coronary artery disease, chronic untreated hypertension, or migraines, benign or malignant liver tumor that developed during the use of OC
  • Known or suspected estrogen-dependent neoplasia
  • Presence of disorders commonly accepted as contraindications to combined OC including: undiagnosed abnormal vaginal bleeding, any neurovascular lesion of the eye or serious visual disturbance, or liver disease
  • Intake any multivitamin or folic acid-containing supplements within 30 days before study admission
  • Used a steroid hormone-containing intrauterine device within 3 months prior to study admission
  • Used any medications that were known cytochrome P-450 enzyme inducers or inhibitors (e.g., St. John's Wort, cimetidine or rifampin), within 60 days before dosing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00709332

Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Investigators
Study Director: Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00709332     History of Changes
Other Study ID Numbers: CR002206
Study First Received: June 30, 2008
Last Updated: June 6, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Norgestimate
Folic Acid
Ortho-Cyclen
Female contraception
Ethinyl Estradiol
Drug Interactions
Pharmacokinetics
Contraceptives, Oral

Additional relevant MeSH terms:
Estradiol
Polyestradiol phosphate
Ethinyl Estradiol
Estradiol valerate
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Contraceptive Agents
Norgestimate
Folic Acid
Vitamin B Complex
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Reproductive Control Agents
Therapeutic Uses
Contraceptive Agents, Female
Hematinics
Hematologic Agents
Vitamins
Micronutrients
Growth Substances
Contraceptives, Oral, Synthetic
Contraceptives, Oral

ClinicalTrials.gov processed this record on September 18, 2014